DexCom, Inc. Stock Börse Stuttgart
Equities
DC4
US2521311074
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
107.2 EUR | -0.37% | -8.27% | -4.51% |
05-30 | Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target | MT |
05-24 | Declaration of Voting Results by DexCom, Inc | CI |
Sales 2024 * | 4.33B 3.98B 5.9B | Sales 2025 * | 5.15B 4.73B 7.02B | Capitalization | 47.23B 43.38B 64.35B |
---|---|---|---|---|---|
Net income 2024 * | 732M 672M 997M | Net income 2025 * | 910M 836M 1.24B | EV / Sales 2024 * | 11.2 x |
Net Debt 2024 * | 1.43B 1.32B 1.95B | Net Debt 2025 * | 994M 913M 1.35B | EV / Sales 2025 * | 9.36 x |
P/E ratio 2024 * |
65.7
x | P/E ratio 2025 * |
53.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on DexCom, Inc.
1 week | -8.27% | ||
1 month | -10.33% | ||
3 months | +2.59% | ||
6 months | +1.62% | ||
Current year | -4.51% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 07-10-31 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 18-08-31 |
Chief Tech/Sci/R&D Officer | 47 | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 09-11-19 |
Mark Foletta
BRD | Director/Board Member | 63 | 14-11-18 |
Eric Topol
BRD | Director/Board Member | 69 | 09-07-08 |
Date | Price | Change |
---|---|---|
24-06-03 | 109.6 | +1.86% |
24-05-31 | 107.6 | -6.82% |
24-05-30 | 115.5 | -1.95% |
24-05-29 | 117.8 | +0.22% |
24-05-28 | 117.5 | +1.15% |
Delayed Quote Börse Stuttgart, June 03, 2024 at 04:44 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.19% | 178B | |
-0.73% | 107B | |
-1.98% | 67.04B | |
+12.32% | 44.62B | |
+9.25% | 42.5B | |
+16.08% | 29.99B | |
+15.97% | 25.22B | |
-6.17% | 24.14B | |
-6.27% | 23.69B |
- Stock Market
- Equities
- DXCM Stock
- DC4 Stock